Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: September 2023

MissionIRNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Announces Commercial Class 3 EV EPA Certification

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has reached a key milestone. The company announced that it has received full approval from the Environmental Protection Agency (“EPA”) with certification for class 3 EV commercial vehicles; the company … Continue reading

Posted in Mullen Automotive Inc. MULN | Leave a comment

Amid REE Market Supply Interruptions, Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Presses Forward With Commercial Processing Plant Plans

This month’s shutdown of Myanmar rare earth mining to prepare for inspections sparked short-term stockpiling and upward pricing for metal products such as terbium oxide and dysprosium oxide used in solid-state devices, a reminder of the vulnerability of many tech … Continue reading

Posted in Ucore Rare Metals Inc. UURAF | Leave a comment

RVL Pharmaceuticals plc (NASDAQ: RVLP) Looking to Capitalize on UPNEEQ’s Significant Potential

RVL Pharmaceuticals (NASDAQ: RVLP), is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis (ptosis, or low-lying eyelids) in adults. The company believes there is significant potential for … Continue reading

Posted in RVL Pharmaceuticals plc. RVLP | Leave a comment

MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Receives EPA Certification for Class 3 EV Commercial Vehicles

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced its achievement of a key milestone with full approval from the Environmental Protection Agency (“EPA”) with certification for Class 3 EV Commercial Vehicles received on Sept. 22, 2023. … Continue reading

Posted in Mullen Automotive Inc. MULN | Leave a comment

Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study

Cancer drug developer CNS Pharmaceuticals (NASDAQ: CNSP) is closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (“GBM”), with 200 of the expected 243 patients now enrolled in the company’s … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) K5 Security Robot Deployed in NYPD Pilot Program

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, has announced that the city of New York and the New York Police Department (“NYPD”) launched the Knightscope K5 security robot service. The move … Continue reading

Posted in Knightscope Inc. KSCP | Leave a comment

MissionIRNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Making Significant Strides to Advance Cellular Therapy Programs

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. “The company is guided by the mission to advance cell-based product candidates … Continue reading

Posted in Longeveron Inc. LGVN | Leave a comment

MissionIRNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Anticipating Growing Demand for UPNEEQ(R)

RVL Pharmaceuticals (NASDAQ: RVLP) is a a specialty pharmaceutical company whose near-term focus is to continue the rollout of UPNEEQ(R) into the medical aesthetics market through its dedicated sales force. “UPNEEQ(R) is the first non-surgical treatment option approved by the … Continue reading

Posted in RVL Pharmaceuticals plc. RVLP | Leave a comment

MissionIRNewsBreaks – Why PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

PaxMedica (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “The company’s lead programs are focused … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – Fintech Ecosystem Development Corp. (NASDAQ: FEXD) Carving out Share in Challenger Bank, Crypto Markets

Fintech Ecosystem Development Corp. (NASDAQ: FEXD), through strategic mergers and acquisitions, is helping to accelerate the growth of the challenger bank market. “In turn, the company is making financial services affordable and accessible, particularly to individuals in emerging markets, who … Continue reading

Posted in Fintech Ecosystem Development Corp. FEXD | Leave a comment